Pharmacor challenges patent extension for Biogen’s MS drug
Ben Mee 2021-09-23 2:14 pm By Bianca Hrovat | Sydney
Please login to bookmark Close

An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug  was wrongly granted.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au